Flame retardant polybrominated diphenyl ethers (PBDEs) are a class of persistent organic pollutants (POPs). 2,2ʹ,4,4ʹ-Tetrabromodiphenyl ether (BDE-47) is a representative PBDE congener with widespread distribution and relatively high toxicity potential. Although it has been reported that BDE-47 can cause DNA damage in various in vitro systems, few studies have provided in vivo genotoxicity information. The aim of the present study was to investigate the genotoxicity of BDE-47 in mice. Male gpt delta mice were administered BDE-47 by gavage at 0, 0.0015, 1.5, 10 and 30 mg/kg/day, and 6 days per week for six consecutive weeks. Before the first treatment, and at 2.5 and 5 weeks after the first treatment, peripheral blood was collected from tails and the micronucleus assay and the Pig-a gene mutation assay were performed. After the last treatment, the mutant frequencies of the gpt gene in the liver and the germ cells from seminiferous tubules were determined. All these assays failed to produce positive results, suggesting that BDE-47 was neither clastogenic nor mutagenic in both target and non-target tissues in gpt delta mice.
Introduction
Polybrominated diphenyl ethers (PBDEs), a class of widely used brominated flame retardants in numerous commercial products, have raised global concern over their health risks in recent years. Since 1970s, PBDEs have been found to be widely distributed in the environment and the biota (1) . PBDEs and their metabolites have been reported to have neurodevelopmental toxicity, endocrine disruption effects, reproductive toxicity, hepatoxicity and potential carcinogenicity (2) (3) (4) (5) . In 2009, commercial penta-and octa-PBDE mixtures were officially classified as persistent organic pollutants (POPs) under the Stockholm Convention (6) . Recently, decabromodiphenyl ether (BDE-209) was listed in Annex A of the Stockholm Convention (6).
2,2ʹ,4,4ʹ-Tetrabromodiphenyl ether (BDE-47) is one of the major components of commercial penta-PBDE mixtures (7) . It is among the most prevalent and abundant PBDE congeners present in the environmental and biological samples (1) . As evidence on this, the 2007/2008 National Health and Nutritional Examination Survey showed that the mean serum concentrations for BDE-47 were higher than other measured PBDE congeners in all age groups (8) . One may assume that BDE-47 will not be a concern now because its production and use were banned in large parts of the world, including the European Union in 2004 (2, 4) . However, this assumption is apparently not true due to its persistency. Despite the ban on its production and use, BDE-47 keeps leaking out from the materials manufactured before the restrictions are imposed. In addition, BDEreduce spermatogenesis, induce germ cell apoptosis, and impair sperm motility and capacitation in mice and rats (9, 15) . In humans, it was found that sperm mobility was negatively related to the serum level of BDE-47 (16) . BDE-47 also exhibited the endocrine disruption effect; BDE-47 exposure was reported to be associated with the changes in thyroid hormone and sex hormone in both humans and animals (5, (16) (17) (18) . Importantly, BDE-47 may be more toxic compared with the PBDE congeners carrying more bromine atoms due to its higher volatility, water solubility and bioaccumulative effect (19) . Indeed, BDE-47 showed higher potency to induce apoptosis and oxidative stress than 2,2′,4,4′,5-pentabromodiphenyl ether (BDE-99), 2,2′,4,4′,5,5′-hexabromodiphenyl ether (BDE-153) and BDE-209 in mouse cerebellar granule neurons (20) , and tetra-PBDEs were observed to be more genotoxic than penta-, octa-and deca-PBDEs in chicken DT40 cells (4) .
The genotoxicity of BDE-47 has also been investigated. In an in vitro gene mutation assay, BDE-47 showed no mutagenic activity in Salmonella typhimurium strains TA98, TA100 and TA102 with and without metabolic activation enzymes (5). However, BDE-47 has been reported to cause double strand breaks, single strand breaks, or chromosome aberrations in a variety of cell types, including human SK-N-MC cells (21) , chicken DT40 cells (4), rat hippocampal neurons (22) , human SH-SY5Y cells (23) , HepG2 (24), etc. A vast majority of studies on this subject only investigated the in vitro genotoxicity of BDE-47 with studies of the in vivo genotoxicity of BDE-47 have been very scarce. To our knowledge, only two studies concern the in vivo genotoxicity of BDE-47. In 2006, Barsiene et al. (25) reported that BDE-47 induced micronuclei and other nuclear abnormalities in gills of blue mussels. Jiang et al. (26) reported that BDE-47 exposure caused a concentration-dependent increase in the micronucleus frequency in haemocytes of blue mussels, thus affecting the immune function of haemocytes. However, both studies were conducted in blue mussel, a marine organism, rather than a mammalian animal.
Recently, the United States National Toxicology Program (NTP) issued a technical report (TR 589), in which DE-71, a commercial mixture of tetra-and penta-PBDEs containing 36% BDE-47, was found to have hepatocarcinogenic activity at 50 mg/kg in Wistar Han rats, and at 30 and 100 mg/kg in B6C3F1/N mice (5). Because BDE-47 is a major component of DE-71, it is reasonable to assume that BDE-47 may contribute to carcinogenicity of DE-71. The results, together with the scarcity of the in vivo genotoxicity data of BDE-47, warrant an investigation of BDE-47 genotoxicity on a mammalian model.
Thus, in the present study, we employed the gpt delta transgenic mice, a well-established animal model which can detect the gene mutation in specific tissues (27, 28) , to access the in vivo genotoxicity of BDE-47. We used the peripheral blood micronucleus assay to evaluate the chromosomal damage, and Pig-a gene mutation assay and gpt gene mutation assay to examine the mutagenicity of BDE-47. The Pig-a assay is a recently developed in vivo assay, which is used to measure the induction of mutations at the Pig-a gene by scoring the frequencies of mutant phenotype erythrocytes or immature erythrocytes (29) . The gpt gene mutation assay was performed in the liver and germ cells from seminiferous tubules because DE-71 exhibited hepatocarcinogenicity and BDE-47 showed reproductive toxicity.
Materials and methods

Animals and animal treatment
The C57BL/6J gpt delta mice were kindly provided by Dr. Nohmi of the National Institutes of Health Sciences, Japan (27) . Animals were acclimatized in Specific Pathogen Free rooms with the temperature at 20-26°C, the humidity at 30-70%, and a 12-h light/dark cycle for at least 1 week. Regular laboratory chow and filtered tap water were allowed ad libitum. Seven to eight weeks-old male gpt delta mice were randomly divided into four dosage groups (n = 6 per group), a solvent control group (n = 6) and a positive control group (n = 4) by body weight. After 1-week acclimatisation, animals were treated with 0 (the solvent control), 0.0015, 1.5, 10 and 30 mg/kg/day BDE-47 (CAS No. 5436-43-1, Matrix Scientific, SC; dissolved in soybean oil) by gavage at frequencies of 6 days per week for six consecutive weeks. The positive control group was treated with 50 mg/kg/day benzo[a]pyrene (BaP, Sigma-Aldrich, MO) by intraperitoneal injection at a frequency of 1 day per week for six consecutive weeks.
During the treatment, blood samples were collected from the tails. Twenty-four hours after the last treatment, the mice were sacrificed, and the liver and testis tissues were harvested. The dissected tissues were quickly frozen in liquid nitrogen and then stored at −80°C for the gpt mutation assay.
Peripheral blood micronucleus assay
The blood samples for the micronucleus assay, which were collected before the first treatment (i.e. 0 week), and at 2.5 and 5 weeks after the first treatment, were quickly smeared on the acridine orange pre-coated glass slides. After drying, the slides were observed under the fluorescent microscopy with a blue filter and a 40× objective (IX73, Olympus, Japan). A total of 2000 polychromatic erythrocytes (PCEs) were examined and the micronulcleated PCEs (MNPCEs) were counted. The micronucleus frequencies were calculated as the ratios of MNPCEs to PCEs.
Pig-a gene mutation assay
The EDTAK 2 anticoagulated blood samples were collected at the same time points as above. The Pig-a assay was performed as described previously (29, 30) . Briefly, whole blood samples (1 μl) were double-labeled with FITC-anti-mouse CD24 (BD Pharmingen, Cat# 553261, CA) and APC-anti-mouse TER-119 (BD Pharmingen, Cat# 557909, CA). An unstained control and two single-labeled ones were employed for flow cytometer gating. After labeling, the samples were analyzed with a BD Accuri C6 Flow Cytometer equipped with the C6 software (BD Biosciences, CA). Single cells labeled with APC-TER-119 were gated as red blood cells (RBCs). Among gated RBCs, cells double-labeled with APC-TER-119 and FITC-CD24 were defined as normal ones, whereas those only single-labeled with APC-TER-119 were counted as Pig-a mutated RBCs. The Pig-a gene mutant frequencies (MFs) were calculated as the fractions of Pig-a mutated RBCs in 1 000 000 collected RBCs.
The RET (reticulocyte) assay was also performed to estimate the hematopoietic functions of the subjects. Similarly to the Pig-a assay, the blood samples were double-labeled with APC-TER-119 and PE-anti-mouse CD71 (BD Pharmingen, Cat# 553267, CA), which were used to label RBCs and RETs, respectively. The percentages of RETs (RET%) were calculated as the fractions of PE-CD71-stained cells in 50 000 RBCs.
In vivo gpt gene mutation assay
The in vivo gpt gene mutation assay was performed as described previously by Nohmi et al. (28) . High-molecular-weight genomic DNA from the liver and germ cells of seminiferous tubules was extracted using the RecoverEase DNA Isolation Kit (Agilent Technologies, CA). For the liver, DNA was extracted according to the manufacturer's instructions. For the germ cells of seminiferous tubules, the frozen testis tissues were first thawed on ice for about 30 min and the epithelial capsules were then gently discarded to release the seminiferous tubules. A glass 5-mm-diameter roller was used to squeeze the seminiferous tubules to release the cells of various spermatogenic cell types, including spermatogonia, spermatocyte, spermatid and sperm (31, 32) . The collected cells were then used to isolate DNA following the manufacturer's instructions.
The lambda EG10 DNA was rescued as phages by in vitro packaging reaction using Transpack Packaging Extract (Agilent Technologies, CA) according to the manufacturer's instructions. The rescued phages containing gpt and the chloramphenicol (Cm) acetyltransferase resistance gene were then used to infect the Escherichia coli strain YG6020 and the transgenes were converted into plasmids with the Cre recombinase expressed by YG6020. The bacteria harboring the plasmids carrying mutated gpt gene were selected on culture media containing Cm and 6-thioguanine (6-TG). The bacteria with gpt mutants can grow on plates to form colonies after being incubated at 37°C for 4 days. The gpt gene MFs were calculated by dividing the numbers of Cm + 6-TG resistant colonies by those of Cm resistant ones, which represent the numbers of colonies with rescued plasmids.
Statistical analysis
All results are expressed as mean ± SD. The frequencies of micronucleus, Pig-a mutant, and gpt mutant were log-transformed with the base being 10. The Dunnett-t test was then used to determine the statistical significances of differences between BDE-47 treated groups and the solvent controls after the one-way ANOVA was performed. For the conditions of heterogeneity of variances among treatment groups, the nonparametric test was applied. The differences between the positive controls and the solvent ones were evaluated with the Student's t test. For RET%, same analyses were performed without log-transformation of the data. A value of P < 0.05 was considered statistically significant.
Results
Male transgenic mice were administered BDE-47 for 6 weeks via gavage. Time-dependent changes of the peripheral blood micronucleus frequencies and Pig-a MFs were measured during the treatment. After the 6-week treatment, the measurements of gpt MFs were performed in both the liver and germ cells. During the treatment, no obvious signs of toxicity and no significant differences in the body weight gains were observed in all groups.
The peripheral blood micronucleus frequencies in BDE-47-treated mice
To investigate the chromosomal damage induced by BDE-47, we collected peripheral blood for the micronucleus assay at three time points: before the first treatment (i.e. 0 week), and at 2.5 and 5 weeks after the first treatment. As shown in Table 1 , the baseline micronucleus frequencies (0 week) showed no significant differences among the groups. After the treatment, the micronucleus frequencies of BDE-47-treated groups at 2.5 and 5 weeks still showed no significant increases compared with those of the solvent controls, whereas the BaP-treated mice displayed elevated micronucleus frequencies in comparison with those of the solvent controls and the differences were statistically significant (P < 0.05).
The Pig-a gene MFs in BDE-47-treated mice
As shown in Table 2 , at 2.5 and 5 weeks after the first treatment, the Pig-a gene MFs of the BaP-treated group showed 4.2-and 2.7-fold increases compared with those of the solvent control group. By contrast, after the treatment, the Pig-a gene MFs of the BDE-47-treated groups failed to show significant increases compared with those of the solvent controls at 2.5 and 5 weeks. However, the RET% of the BDE-47-treated groups showed a dose-dependent increase at 5 weeks after the first treatment (Table 3 ). The BaP-treated animals exhibited a statistically significant increase in RET% at both 2.5 and 5 weeks after the first treatment (P < 0.05).
The gpt gene MFs in BDE-47-treated mice
To calculate the MFs of gpt gene in the liver and germ cells, 180 000-1 835 000 Cm-resistant colonies derived from rescued phages per mouse were analyzed. As shown in Tables 4 and 5 , in both liver and germ cells, the gpt gene MFs of the BDE-47-treated groups with the highest dose did not exhibit statistically significant differences from those of the solvent controls. In the liver, the MF of the positive control group was significantly higher than that of the solvent control group (P < 0.05). However, the MF of the positive control in the germ cells did not show significant difference from that of the solvent control. 
Discussion
To date, few in vivo studies have investigated the genotoxicity of PBDEs, even though some PBDEs have carcinogenic potential. Considering the growing concerns regarding environmental contamination and human exposure to BDE-47, and the positive results from in vitro genotoxic studies, it is important to clarify whether BDE-47 can cause genotoxicity with in vivo models. Hence, in the present study, we used gpt delta transgenic mouse model to investigate the genotoxicity of BDE-47. Our results suggested that BDE-47 exhibited neither clastogenic nor mutagenic effect in both target and non-target tissues in gpt delta mice.
To validate the observations, it was noted that the dose levels and administration period were appropriate. The lowest dose used was 0.0015 mg/kg/day, which, considering the species variations, is higher than the estimated intake of PBDEs (7.1 ng/kg/day for adults) based on the data of the U.S. Environmental Protection Agency (1). The highest dose (30 mg/kg/day) is about 300 000-fold higher than the estimated environmental exposure level, which is expected to be sufficient to reveal the toxicity of BDE-47 in general population. At such a high dose, BDE-47 has been reported to induce germ cell loss and apoptosis (15) . In addition, according to the OECD guidelines (33), treatment with BDE-47 for 6 weeks is considered acceptable to detect mutations. In mice, it takes about 49 days for spermatogonial stem cells to become mature sperm. Phases passed during a 6-week administration include differentiated spermatogonia, spermatocyte, spermatid and sperm. By examining germ cells in seminiferous tubules, the mutagenicity of BDE-47 in almost all spermatogenesis phages can be detected.
The level of BDE-47 in the serum was determined at the end of the experiments. BDE-47 and its metabolites were observed with the concentrations ranging from 100 to 1000 ng/g in 1.5 mg/kg/day and 30 mg/kg/day groups (data not shown). Moreover, the RET% in peripheral blood increased in a dose-dependent manner during the treatment of BDE-47 (Table 3) , indicating the exposure and toxic effect of BDE-47 in the bone marrow. For the germ cells, as reported in a previous study, BDE-47 could induce germ cell loss and apoptosis at ≥0.045 mg/kg/day (15) . In the present study, reproductionrelated proteins were observed to be altered in the treated groups (data not shown). The liver is known as a target organ for PBDEs. In a previous study, a single oral dose of 1 μmol/kg BDE-47 could cause measurable deposition in the liver tissue, suggesting that the higher dose in our study was sufficient for liver exposure (34) . Taken together, all these data demonstrated that the exposure of BDE-47 was adequate in the examined tissues in our study.
The data of the positive control group may be a concern. In our experiments, a positive control group (i.e. the BaP-treated group) was set and the micronucleus frequencies of this group indeed exhibited statistically significant increases, albeit small. The group also gave positive results in the Pig-a gene mutation assay and the gpt gene mutation assay in the liver. The only issue about the positive control group was that the gpt gene MFs in germ cells failed to exhibit statistically significant increases compared with the negative control. However, there were similar reports in the literature. For example, it was reported that male MutaMouse mice administered BaP by gavage at 50 mg/kg/day for 28 consecutive days did not show statistically significant increases in the MF of the germ cells from the seminiferous tubules (32) , suggesting that germ cells may not be sensitive to BaP treatment. Overall, these results were comparable with the published data (32, 35, 36) . Thus, it appeared that these assays were able to detect genotoxicity of genotoxins.
Since BDE-47 showed no genotoxicity in in vivo transgenic mice model, it may play a non-genotoxic role in the carcinogenesis of DE-71. As endocrine disruptors, many reports on the association between PBDEs and induction of some hormone-dependent tumor have been published. For example, a case-control study suggested a possible correlation between the BDE-47 level and breast cancer (37) . In another in vitro study, BDE-47 or its metabolites were observed to stimulate proliferation in both OVCAR-3 ovarian cancer cells and MCF-7 breast cancer cells accompanied by endocrine disruptions (38) . It was found that BDE-99 could trigger epithelial-mesenchymal transition, and increase migration and invasion in colorectal cancer cells (39) . Thus, BDE-47 might exert a tumor promotion effect, which may be associated with its endocrine disruption effect.
Epigenetic alternation is also thought to be connected with the tumor development. A few studies have reported the epigenetic effects of PBDEs. In human placenta samples, the PBDE levels were observed positively associated with the global methylation levels (40) . Another study showed that the cord blood TNFα methylation was negatively associated with maternal BDE-47 exposure (41) . In mice, perinatal exposure to BDE-47 could induce global hypomethylation of the offspring brain DNA (42) . Thus, it was reasonable to speculate that BDE-47-induced DNA methylation alternation could be another possible mechanism for its toxic effect. Further studies are needed to uncover the relationships between BDE-47 exposure and tumorgenesis.
In summary, our results revealed that BDE-47 showed no genotoxicity in the liver, germ cells, and the non-target site in gpt delta transgenic mice, suggesting that BDE-47 might act as a non-genotoxic agent. These findings may thus suggest that further investigations should be focused on non-genotoxic mechanisms of BDE-47. Funding This work was supported by the grants from the National Natural Science Foundation of China (grant number 21477078).
